Department of Community Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Students' Research Committee, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Exp Med Biol. 2021;1291:251-263. doi: 10.1007/978-3-030-56153-6_15.
Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints, which is prevalent in about 0.5-1.0% of the world population. Newer therapies for RA have only minimal efficacy in some cases and some adverse effects. Curcumin with anti-antioxidant, anti-inflammatory, and immunomodulatory properties might have beneficial effects on RA. We have carried out a systematic review with the main aim of estimating the effect of curcumin supplementation on RA. A systematic search of the medical databases, PubMed, Scopus, ISI, and Google Scholar was performed up to March 21, 2020 to identify clinical trials assessing the effect of turmeric or curcumin on RA. Six studies, comprising 259 patients with RA of 6-12 weeks duration, were included. Disease activity was assessed using 28 joints (DAS-28), visual analog scale (VAS), and American College of Rheumatology (ACR-20) scores. Treatment with curcumin significantly reduced DAS-28 scores in four out of five studies and VAS scores for pain in all three studies and significantly increased ACR-20 scores in all three studies in which it was measured. Erythrocyte sedimentation rate (ESR) and circulating C-reactive protein (CRP) were assessed in six and five studies, respectively, out of which four studies reported significant reductions in these parameters in response to curcumin treatment. Rheumatoid factor (RF) was significantly reduced after consumption of curcumin in all three relevant studies. None of the studies reported serious adverse effects with curcumin consumption. The present systematic review suggests that curcumin could be used as a safe agent to treat RA. Thus, further validation is justified.
类风湿关节炎（RA）是一种关节慢性炎症性疾病，在全球约 0.5-1.0%的人群中流行。RA 的新型治疗方法在某些情况下仅具有最小的疗效，并且存在一些不良反应。具有抗氧化、抗炎和免疫调节特性的姜黄素可能对 RA 具有有益作用。我们进行了一项系统评价，主要目的是评估姜黄素补充剂对 RA 的影响。系统检索了医学数据库、PubMed、Scopus、ISI 和 Google Scholar，以确定评估姜黄或姜黄素对 RA 影响的临床试验。共纳入了 6 项研究，包含 259 例病程 6-12 周的 RA 患者。使用 28 个关节（DAS-28）、视觉模拟评分（VAS）和美国风湿病学会（ACR-20）评分评估疾病活动度。姜黄素治疗可显著降低五项研究中的四项 DAS-28 评分和三项研究中的所有 VAS 疼痛评分，并显著增加三项研究中均测量的 ACR-20 评分。六项和五项研究分别评估了红细胞沉降率（ESR）和循环 C 反应蛋白（CRP），其中四项研究报告姜黄素治疗可显著降低这些参数。在所有三项相关研究中，类风湿因子（RF）在姜黄素摄入后均显著降低。没有研究报告姜黄素摄入后出现严重不良反应。本系统评价表明，姜黄素可用作治疗 RA 的安全药物。因此，有理由进一步验证。
